Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OMTX705
- Development stage
- Phase 1
- Lead developer
- Oncomatryx
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
OMTX705 is a first-in-class antibody-drug conjugate (ADC) developed to target the tumor microenvironment in advanced solid tumors. It specifically binds to fibroblast activation protein alpha (FAPα), which is highly expressed on cancer-associated fibroblasts (CAFs) that play a key role in tumor progression and resistance to therapy. The drug consists of a humanized anti-FAP antibody linked to a novel cytolysin payload. Its dual mechanism of action includes direct cytotoxicity via tubulin inhibition and modulation of the tumor stroma, enhancing immune cell infiltration and overcoming resistance to immunotherapy. Preclinical studies have demonstrated potent antitumor activity as both monotherapy and in combination with chemotherapy or immunotherapy, including efficacy in models resistant to PD-1 inhibitors.
- Other names
- Anti-FAPα:Cytolysin ADC
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on OMTX705.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OMTX705.